Kornimate/medical-research-clean huggingface dataset:
the effect of mirror therapy on upper extremity motor function in stroke rehabilitation

Conditions: Stroke; Chronic Stroke Patients; Hemiplegia

Summary: the study aimed to determine the effect of mirror therapy versus conventional physical therapy treatment in improving upper extremity impairments and motor function among chronic hemiplegic subjects. research objectives: 1. to discover the effectiveness of conventional physical therapy treatment on improving upper limb motor function among chronic hemiplegic subjects. 2. to find out the effect of mirror therapy along with conventional physical therapy treatment on improving upper limb motor function among chronic hemiplegic subjects. 3. to find out the effectiveness of mirror therapy combined with conventional physical therapy treatment versus conventional physical therapy treatment alone on improving upper extremity motor function among chronic hemiplegic subjects.


Eligibility criteria:
inclusion criteria: * duration of stroke more than six months * subjects of chronic stroke with left or right hemiplegia. * genders of male and female with age ranging between forty-five to sixty-five years. * mmse scores greater than 23 out of 30. * scored one or one plus on mas on all muscles of the affected upper limb. * have normal visual perception. * able to follow oral commands. exclusion criteria: * unable to follow visual and oral commands. * unilateral neglect. * cognitive impairments (mmse scores less than 24 out of 30), or language deficits. * any other neurological disorders and recent surgeries. * previous exposure to mt.

Keywords: storke hemiplegia mirror therapy upper extremity motor function
oral vitamin d2 for prevention of covid-19

Conditions: Healthy Volunteers

Summary: a total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin d2 and the group not taking vitamin d2. participants in the group taking vitamin d2 orally will receive 200,000 iu of vitamin d2 on the first day of the trial, and again two weeks later (200,000 iu) . the group that will not receive vitamin d2 will not receive any intervention. the whole trial will laste four weeks.

this study is a randomized controlled multicenter clinical trial. participants who meet the inclusion criteria can be included in this trial after signing informed consent. a total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin d2 and the group not taking vitamin d2. participants in the group taking vitamin d2 orally will receive 200,000 iu of vitamin d2 on the first day of the trial, and again two weeks later (200,000 iu) . the group that will not receive vitamin d2 will not receive any intervention. the whole trial will laste four weeks. throughout the trial, participants' nucleic acid or antigen results, 25(oh)d concentrations, etc., need to be tested.

Eligibility criteria:
inclusion criteria: 1. willing to participate in the clinical study and sign the informed consent; 2. staff members of peking university third hospital, including the hospital headquarters, capital international airport hospital, north hospital, beijing haidian hospital, peking university third hospital yanqing hospital and peking university third hospital chongli hospital; 3. test negative for covid-19 antigen and have no symptoms related to covid-19. exclusion criteria: 1. hospital staff with serious underlying diseases; 2. pregnant and lactating women; 3. long-term vegetarians; 4. long-term chronic diarrhea, history of subtotal gastrectomy, biliary obstructive disease and pancreatic disease.
effectiveness of press tack needle acupuncture in treating lactation insufficiency

Conditions: Lactation; Insufficient, Partial; Hypogalactia, Without Mention of Attachment Difficulty

Summary: this study was meant to see the effectiveness of press tack needle acupuncture in improving lactation insufficiency. the acupuncture points used in this study were cv17 danzhong and si1 shaoze. press tack needles were placed in these acupuncture points for 7 days in hope that it will give continuous acupuncture stimulation that might help in improving lactation insufficiency with minimal side effect, less time consuming, and more efficient for the patient.


Eligibility criteria:
inclusion criteria: * breastfeeding mother who suffers from lactation insufficiency * breastfeeding mother from 2 weeks to 5 months post-partum * breastfeeding mother with healthy baby exclusion criteria: * subject consumes drugs that are known to decrease breastmilk production * subject with infection or inflammation in the intended acupuncture points * subject with bleeding disorder * subject consumes anticoagulant * subject with known diabetic history * subject with body temperature \> 38 degree celcius

Keywords: acupuncture exclusive breastfeeding breastmilk press tack needle lactation insufficiency
study of comparison the treatment effect between gastric bypass and exenatide in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: objectives: to investigate the treatment effect between gastric bypass and exenatide in type 2 diabetes in our hospital, in order to investigate the possible mechanism of gastric bypass and exenatide.

methods: 60 type 2 diabetes in our hospital will divide into 3 groups: group a (20 patients who give basal treatment), group b (20 patients who give basal and exenatide treatment, group c（20 patients who give basal and gastric bypass treatment). the age, height, weight, blood glucose, glycosylated hemoglobin a1c（hba1c）,homeostasis model assessment(homa-ir), lipid, blood pressure, course of disease, ejection fraction (ef), fractional shortening(fs), diameter of left ventricle in late diastolic stage(lvedd), the thickness of the ventricular septa（ivsd) and the posterior wall of the right ventricle in late diastolic stage (lvpwd) will record respectively. left ventricular mass index (lvmi), relative wall thickness (rwt) will calculate and high-sensitive c-reactive protein (hscrp), adiponectin and tumor necrosis factor-α（tnf-α） will detect as baseline. after each group's treatment, change from baseline of all indexes will record, multifactor logistic regression will be analyzed the correlations between each positive indexes.

Eligibility criteria:
inclusion criteria: 1. bmi ≥ 35kg/m2, with type 2 diabetes; 2. bmi32-34.9kg/m2, with type 2 diabetes, insulin therapy in combination with oral administration of drugs for 6 months and hba1c ≥ 7%; 3. between the ages of 18-60 years; 4. course of type 2 diabetes ≤ 5 years; 5. ica, iaa, gad are negative , c-peptide level is not less than 0.3mg / l; exclusion criteria: 1. non-diabetic patients , type 1 diabetes (serum insulin antibodies (ica) or glutamic acid decarboxylase antibodies (gada)-positive autoimmune diabetes), special type of diabetes, gestational diabetes; 2. patients who had liver or renal failure 3. severe infections in patients and patients who had cerebrovascular disease 4. patients who had heart failure 5. fasting serum insulin or 2-hour postprandial serum insulin were lower than normal (\<20mmol / l) 6. course of diabetes\> 5 years or age\> 60 years or age \<18 years

Keywords: type 2 diabetes gastric bypass glp-1 adiponectin
expanded access program of zidesamtinib (nvl-520) for patients with advanced ros1+ nsclc or other ros1+ solid tumors

Conditions: Non Small Cell Lung Cancer; ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Summary: the expanded access program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.

the purpose of this expanded access program is to provide access to zidesamtinib (nvl-520) an investigational therapy for eligible patients with ros1 fusion-positive advanced non- small cell lung cancer (ros1+ nsclc) who have previously received ≥ 1 prior ros1 tyrosine kinase inhibitor (tki) or eligible patients with other ros1-positive solid tumors who have previously received any prior commercially-available or investigational therapy, and lack satisfactory therapeutic alternatives and are unable to access zidesamtinib through a clinical trial.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. histologically or cytologically confirmed locally advanced or metastatic nsclc or other solid tumor with documented ros1 rearrangement. 3. previously received at least 1 prior ros1 tki, with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician. 4. enrollment in a clinical trial of zidesamtinib is not possible. 5. adequate organ function and bone marrow reserve. exclusion criteria: 1. prior receipt of zidesamtinib. 2. previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol. 3. ongoing anti-cancer therapy. 4. eligible for ongoing clinical trial with zidesamtinib
laboratory characteristics in chronic atrophic acrodermatitis

Conditions: Chronic Atrophic Acrodermatitis

Summary: the main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with borrelia burgdorferi sensu lato.


Eligibility criteria:
inclusion criteria: * chronic atrophic dermatitis in patients \>18 years exclusion criteria: * none

Keywords: chronic atrophic acrodermatitis lyme borreliosis molecular characteristics outcome
cerebral magnetic resonance spectroscopy at term corrected age and dysexecutive syndrome in very preterm children at 5.5-years-old

Conditions: Preterm Birth

Summary: background: compared to term-born peers, very preterm children generally perform poorly in executive functions, with a significant impact on learning at school and quality of life. these ef deficits are related to microstructural abnormalities in white matter and subcortical brain structure. objective: to investigate if an alteration of cerebral metabolism in very premature at term corrected-age correlates to executive dysfunctions at school age. design, setting, patients: very preterm patients eligible for epirmex underwent cerebral magnetic resonance imaging at term-equivalent age and 1h-mrs using a monovoxel technique. the volumes of interest were the posterior periventricular white matter zone and the basal ganglia and thalamus the ratios of n acetyl aspartate (naa) to choline (cho), naa to creatine(cre), cho to cr, and lac (lactate) to cr were calculated. main outcome measures: survival at 5 ½ years with or without neurodevelopmental disabilities (composed of cerebral palsy, visual, hearing, cognitive deficiency, behavioral difficulties, or developmental coordination disorders) were described. the executive functions were assessed using two indices from the wechsler intelligence scale measured in the epipage 2 cohort at age five-and one-half years: the working memory index (wmi) and the fluid reasoning index (fri).


Eligibility criteria:
inclusion criteria: * inclusion criteria form epipage2 and epirmex * children who underwent spectroscopy with regions of interest analyzed: periventricular zone, gray nuclei, brainstem. * children who received a complete cognitive assessment in epirmex (integrated assessment identical to that planned in epipage2) at age 5 ½. non-inclusion criteria: * children with severe karyotype abnormalities. * children with central nervous system malformations diagnosed antenatally or on neonatal tests * children with severe cerebral palsy or major neurosensory (blindness, profound deafness...) not allowing children to take the tests scheduled at age 5 ½.
scalar localization cochlear electrode array using 64 slice ct

Conditions: Hearing Loss

Summary: insertion of electrode array in scala vestibuli, rather than the preferred location within scala tympani, leads to loss of native hearing in those patients with isolated high-frequency hearing loss undergoing cochlear implantation.

we aim to determine the surgical placement in patients with high frequency who had long electrode array insertions because they did not meet audiometric criteria for short array devices. from this basis we will be able to determine if suboptimal insertion (e.g., in the scala vestibuli) leads to loss of low-frequency hearing in these patients. we also will look at the possibilities of using this data in predicting outcomes, modifying implant design, and perfecting surgical technique.

Eligibility criteria:
inclusion criteria: * registered in the cochlear implant database. * patient has short or long electrode cochlear implant for high frequency hearing loss. exclusion criteria: * inability to provide consent. * patients with underlying otospongiosis, extensive labyrinthitis ossificans or cochlear dysplasia. (these patients would have been identified with pre-operative imaging prior to cochlear implantation).

Keywords: cochlear hearing high frequency hearing loss
definitive therapy for oligometastatic solid malignancies

Conditions: Stage IV or Recurrent Carcinoma or Sarcoma

Summary: patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. in the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.

up to recently it has been assumed that in the setting of metastatic solid tumors, locoregional control of clinically apparent metastases does not substantially impact survival due to undetectable micrometastic (clinically not visualized) disease that ultimately lead to treatment failure/progression. however, as more advanced systemic therapy continue to improve control of micrometastatic disease, failures at the original sites of disease remain common. furthermore, some studies have shown locoregional treatment of limited clinical metastases to actually improve survival. therefore, the investigators hypothesize that aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival or alter the course of the disease in some patients with limited metastatic disease.

Eligibility criteria:
inclusion criteria: * 4 or less distinct sites of active disease. locoregional disease counts as one site * all sites of disease can safely be encompassed by radiation fields to doses ≥ 45 gy (biologic equivalent dose) and/or removed completely with surgery and/or completely ablated with other appropriate site-specific techniques. * sufficient blood cell counts and adequate liver function exclusion criteria: * hematologic malignancies * distinct sites of disease \> 4 * karnofsky performance status \< 70 * unexplained weight loss \> 10 % * hiv, chronic viral hepatitis, or any chronically active infection * life expectancy \< 6 months for any reason

Keywords: oligometastases metastatic cancer stereotactic radiosurgery
phase iii cat-pad study

Conditions: Rhinoconjunctivitis

Summary: the purpose of this study is to compare the treatment effect of two treatment regimens of cat-pad vs placebo and to evaluates the treatment effect of cat-pad on symptoms, rescue medication usage and quality of life.


Eligibility criteria:
inclusion criteria * male or female, aged 12-65 years. * moderate to severe rhinoconjunctivitis on exposure to cats for at least 2 years. * subjects may optionally also have gina step 1 controlled asthma. * positive skin prick test to cat hair. * cat dander specific ige ≥0.35 ku/l. exclusion criteria * asthma falling under the gina definitions "partly controlled" and "uncontrolled" or steps 2 to 5. * fev1 \<80% of predicted. * clinically significant confounding symptoms of allergy to seasonal allergens during the final evaluation period. * skin prick test 5 mm greater than the negative control to perennial allergens or animal dander (other than cat) which cannot be avoided during the study. * significant symptoms of another clinically relevant illness that is likely to affect scoring of rhinoconjunctivitis symptoms. * clinically relevant abnormalities detected on physical examination. * history of severe drug allergy, severe angioedema or anaphylactic reaction to food.

Keywords: cat allergy rhinoconjunctivitis
efficacy of ll-37 cream on bacteria colonization, inflammation response and healing rate of diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: diabetic foot ulcer (dfu) is a common complication of diabetes with global prevalence of 6.3%. treatment of diabetic foot ulcer (dfu) is challenging with disappointing outcome. wound debridement, infection control, pressure relief and revascularization are main pillars of dfu management. various substances and modalities are being investigated for their potential effects in treating dfu, one of which is ll-37. in this randomized, controlled trial, 40 patients with uncomplicated dfu will be enrolled. patients are randomly assigned to undergo twice a week treatment with 0.5 mg/ml ll-37 cream (treatment group) or placebo cream (control group) for 4 weeks in addition to standard wound care. the primary outcomes are the healing rate measured by wound area and granulation index and changes in patterns of aerobic bacteria colonization during the 4-week study duration and changes in concentrations of il-α and tnf-α from fluid collected from dfu on the end of the second and third week of study compared to baseline.


Eligibility criteria:
inclusion criteria: * patients with dfu * ankle brachial index (abi) 0.9 - 1.3 * wound area 5 - 20 cm\^2 * wound depth until subcutaneous tissue * without systemic infection, osteomyelitis, septic arthritis, or fasciitis * subjects are willing to participate by signing consent exclusion criteria: * gangrene * on treatment with systemic corticosteroids within 7 days before the start of study * on treatment with systemic antibiotics within 2 days before the start of study * patients with end stage renal disease
maternal grandmothers in the born in guangzhou cohort study

Conditions: Hereditary Transmission; Immune Development; Childhood Obesity; Host and Microbiome; Neurodevelopment

Summary: the mgbig is a study exploring cross-generational effects in 5000 women and their children and grandchildren located in guangzhou, china. its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology and on explaining the cause of the disease from the perspective of "grandmother-mother-child" heredity. data are collected regarding environmental exposures, lifestyle, and social support on grandmother from birth to old age. biological samples including blood and tissue samples are collected.

it was previously believed that heredity strictly follows mendel's laws, but recent studies have found that through placental material exchange, mammals may transfer maternal immune-related factors vertically, thus promoting the protection of "non-heredited maternal antigenic traits". thus, the transmission of reproductive information across generations is realized. since the unusual genetic pattern of the x chromosome, grandmother's influence may be gender specific. since grandchildren were usually took care by grandparents in china, it could be achievable to attach and recruit maternal grandmother together with mother and children. cohort including three generations of women is rare in asia at present. in the mgbig, extensive information including demographic characteristics, lifestyle, history of diseases, mental health, and behaviors is collected from the participants. longitudinal follow up and surveillance of common chronic diseases are also to be conducted. the mgbig intends to recruit maternal grandmothers to study the effects of maternal genetic and environmental exposure on the health of their children and grandchildren.

Eligibility criteria:
inclusion criteria: 1. maternal grandmother' grandchildren delivered in guangzhou women and children's medical center 2. baseline information of maternal grandmother's daughter during pregnancy available exclusion criteria: 1. significant cardiovascular abnormalities 2. intelligent obstacle, intellectual disabilities or gawkish condition

Keywords: maternal grandmother genes immune cohort child development
probiotics and intestinal microbiome in preterm infants

Conditions: Microbial Colonization

Summary: the gut microbiome plays a significant role in balancing the inflammatory system in the immature gut. a breakdown in this balance with altered colonization of the microbiota in very low birth weight (vlbw) preterm infants is associated with increased feeding intolerance, necrotizing enterocolitis (nec) and sepsis. probiotics are proposed to normalize microbial populations and decrease intestinal disease in preterm infants. there is limited data linking clinical outcomes with the biology of probiotics. we aim to study the colonization of the gi tract with probiotic species contained in a specific probiotic blend - florababy - in vlbw preterm infants. stool microbiome will be analyzed at 4 time points in 2 groups (one given florababy and the other no) of infants less than 1000 grams birth weight and \< 29 weeks gestation. a comparison of stool microbiome analysis and the incidence of feeding intolerance and time to reach full feeds in the two groups will be made.


Eligibility criteria:
inclusion criteria: * infants born less than 29 weeks gestation and \<1000 g birth weight admitted to the neonatal intensive care unit (nicu) at foothills medical centre in calgary. exclusion criteria: * infants with major congenital anomalies, hypoxic-ischemic injury, nec or bowel perforation before 72 hours of life.
a study on the effects of vr-3 herbal blend intake on acute and chronic stress in healthy adults

Conditions: Healthy Adults

Summary: the purpose of this study is to determine the safety and efficacy of vr-3 herbal blend and its effects on acute and chronic stress responses.


Eligibility criteria:
inclusion criteria: 1. men and women between the ages of 35-45 2. no health concerns as determined by study physicians 3. women must not be pregnant or become pregnant for the duration of the study. exclusion criteria: 1. the subject has a history of hypersensitivity to any of the compounds used in the study 2. the subject is pregnant or a lactating female. note: if the potential subject is a post-menarcheal female, a pregnancy test (urine or serum) must be performed within 24 hours of study drug administration and confirmed negative in order for the potential subject to be enrolled). 3. history of psychiatric illness or chronic stress or anxiety 4. hypertension, cardiovascular disease, or other health concerns that may confound study results 5. allergy or sensitivity to test product or ingredients 6. individuals who are cognitively impaired or who are not able to give informed consent 7. clinically significant or abnormal laboratory result that can confound the study 8. medication or nutraceutical intake that can interact with the adaptogens or the biomarkers used in the study (to be determined by study physician) 9. previous participation in a clinical research trial within 30 days prior to randomization 10. the subject has an ongoing abuse of illicit substances, alcohol, or actively smoking marijuana. 11. the subject is actively engaging in the use of herbal medicine, traditional chinese medicine, ancient indian medicine, yoga, or ayurveda